Bionano Genomics, Inc. (BNGO) NASDAQ

5.01

+0.01(+0.20%)

Updated at February 05 09:49AM

Currency In USD

Bionano Genomics, Inc.

Address

9540 Towne Centre Drive

San Diego, CA 92121

United States of America

Phone

858 888 7600

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

344

First IPO Date

August 21, 2018

Key Executives

NameTitlePayYear Born
Dr. Robert Erik Holmlin M.B.A., Ph.D.President, Chief Executive Officer & Director and Chief Financial Officer612,6221968
Dr. Alka Chaubey FACMG, Ph.D.Chief Medical Officer452,9111973
Mr. Mark OldakowskiChief Operating Officer472,9111974
Mr. Mark Adamchak CPAVice President of Accounting & Controller0N/A
Mr. Stanislas Marin M.B.A., M.S.Vice President of Global Sales0N/A
Mr. Cory KreeckGlobal Head of People Operations0N/A
Ms. Donna PolizioGlobal Head of Market Access0N/A
Mr. Jonathan Dixon J.D.General Counsel & Secretary01975

Description

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.